Navigation Links
Biopure Sues National Institutes of Health Official
Date:10/28/2008

Complaint Alleges Defamation, Trade Libel and Intentional Interference with

Prospective Business Advantage

CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it had filed an action for injunctive relief and damages against Charles Natanson, M.D., who co-authored an article and several letters about Hemopure, hemoglobin glutamer-250 (bovine), Biopure's oxygen therapeutic product for human use. The action was filed on October 10, 2008, in the U.S. District Court, District of Columbia. Natanson is senior investigator and head of the anesthesia section of the Critical Care Medicine Department, Clinical Center, of the National Institutes of Health.

The complaint alleges that in publishing the article "Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death" (published by the Journal of the American Medical Association online on April 28, 2008) and writing a number of letters to regulatory authorities in jurisdictions where Biopure is active, Natanson engaged in tortious activity that injured Biopure. Biopure seeks injunctive relief and damages for defamation, trade libel/injurious falsehood and intentional interference with prospective business advantage.

Natanson has not yet filed an answer or any other response.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The Company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward- looking statements, including any statements implying that any legal action will be successful. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10- Q filed on September 15, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
9. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
10. International study strengthens case for daily calcium pill
11. Yakima Health Care Leader Tapped for Leadership Post at National Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... ... Recognizing that lifestyle medicine is essential to health and healthcare, About.com ... MD, MPH, president of the American College of Lifestyle Medicine, as their first senior ... said Katz. “There is so much opportunity to add years to lives, and life ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... support for knees, ankles, and elbows. Engineered with athletes in mind, OMNIFORCE ... manufacturing (opposed to ineffective circular knitting, common in the industry) produces premium ...
(Date:5/4/2016)... ... May 04, 2016 , ... With the stamp of ... the month of May as National Cancer Research Month. According to the American ... of cancer with predications of one in four Americans dying as a result. , ...
(Date:5/4/2016)... ... 04, 2016 , ... International Conference on Obesity and Chronic ... at Las Vegas. It aims to bring together academicians, scientists, dietitians, surgeons, physicians, ... across the globe; making the conference a perfect platform to share experience and ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 4, 2016 Global ... pages, profiling 09 key companies and supported with ... and in-depth study on the current state of ... of the industry including definitions, classifications, applications and ... is provided for the international market including development ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology: